Addressing medicine shortages in Europe

2017 Market Review – Biosimilar Medicines Markets – Policy Overview

Value Added Medicines: Time to Adjust the HTA Decision Frameworks

The Impact of Biosimilar Competition in Europe

ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

OPEN

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

OPEN

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

OPEN

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

OPEN

Market Review – European Generic Medicines Markets

Simon-Kucher. Policy Requirements for a Sustainable Biosimilar Market (September 2016)

skp-cover

picto-reportpicto-videopicto-pr

IMS – The Impact of Biosimilar Competition (2016)

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

IMS Institute – Biosimilar Report